犀角地黄汤加味联合司库奇尤单抗注射液治疗中重度银屑病临床研究

Clinical Study on Modified Xijiao Dihuang Decoction Combined with Secukinumab InjectionforModerateto Severe Psoriasis

目的:观察犀角地黄汤加味联合司库奇尤单抗注射液治疗中重度银屑病血热证的临床疗效。方法:选取64例中重度银屑病血热证患者,采用随机数字表法分为对照组和观察组各32例。2组均剔除2例,最终纳入研究各30例。对照组给予司库奇尤单抗注射液治疗,观察组在对照组基础上给予犀角地黄汤加味治疗。2组均治疗2个月。比较2组临床疗效、银屑病皮损面积和严重指数(PASI)评分、皮肤病生活质量指数(DLQI)评分、炎症因子水平及不良反应发生率。结果:治疗后,观察组总有效率93.33%,高于对照组73.33%,差异有统计学意义(P<0.05)。2组PASI、DLQI评分均较治疗前降低,观察组PASI、DLQI评分均低于对照组,差异均有统计学意义(P<0.05)。2组血清白细胞介素-6(IL-6)、白细胞介素-17A(IL-17A)、白细胞介素-23(IL-23)水平均较治疗前降低,观察组血清IL-6、IL-17A、IL-23水平均低于对照组,差异均有统计学意义(P<0.05)。不良反应发生率观察组6.67%、对照组3.33%,2组比较,差异无统计学意义(P>0.05)。结论:在司库奇尤单抗注射液基础上加用犀角地黄汤加味治疗中重度银屑病血热证,可提高临床疗效和患者的生活质量,抑制炎症反应,且安全性好。

Objective:To observe the clinical effect of modified Xijao Dihuang Decoction combined with Secukinumab Injection for moderate to severe psoriasis with blood heat syndrome.Methods:A total of 64 cases of patients with moderate to severe psoriasis with blood heat syndrome were selected and divided into the control group and the observation group according to the random number table method,with 32 cases in each group.Two cases were excluded in both group,and finally 30 cases were included.The control group was treated with Secukinumab Injection,and the observation group was additionally treated with modified Xijiao Dihuang Decoction based on the treatment of the control group.Both groups were treated for 2 months.The clinical effects,the Psoriasis Area Severity Index(PASl)scores,the Dermatology Life Quality Index(DLQl)scores,the levels of inflammatory factors and the incidence of adverse reactions were compared between the two groups.Results:After treatment,the total effective rate was 93.33%in the observation group,higher than that of 73.33%in the control group,the difference being significant(P<0.05).The scores of PASl and DLQI in the two groups were decreased when compared with those beforetreatment,and the above two scores in the observation group were lower than those in the control group,differences being significant(P<0.05).The levels of interleukin-6(IL-6),interleukin-17A(IL-17A),and interleukin-23(IL-23)in serum in the two groups were decreased when compared with those before treatment,and the above three levels in the observation group were lower than those in the control group,differences being significant(P<0.05).The incidence of adverse reactions was 6.67%in the observation group and 3.33%in the control group,there being no significant difference between the two groups(P>O.05).Conclusion:The additional application of modified Xijiao Dihuang Decoction based on Secukinumab Injection for moderate to severe psoriasis with blood heat syndrome can improve the clinical effect and the quality of life of patients and inhibit the inflammatory responses,with good safety.